Yoshiro Murase, Rikiya Takeuchi, Yoshiharu Ohtaki, Makiko Hosoya, Akio Aono, Kinuyo Chikamatsu, Yuta Morishige, Yuriko Igarashi, Joseph Edwin L Bascuña, Gel Anne Marie V Atienza, Angeline Grace A Sedusta, Catherine Ann P L Sacopon, Ramón P Basilio, Midori Kato-Maeda, Satoshi Mitarai
{"title":"MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.","authors":"Yoshiro Murase, Rikiya Takeuchi, Yoshiharu Ohtaki, Makiko Hosoya, Akio Aono, Kinuyo Chikamatsu, Yuta Morishige, Yuriko Igarashi, Joseph Edwin L Bascuña, Gel Anne Marie V Atienza, Angeline Grace A Sedusta, Catherine Ann P L Sacopon, Ramón P Basilio, Midori Kato-Maeda, Satoshi Mitarai","doi":"10.1093/jac/dkag358","DOIUrl":"10.1093/jac/dkag358","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis.</p><p><strong>Methods: </strong>We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation.</p><p><strong>Results: </strong>Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates.</p><p><strong>Conclusions: </strong>These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149286973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yujing Zhang, Guqi Ren, Jing Wu, Jun Xu, Yan Ji, Guiling Li, Zhenyu Wang, Jing Wang, Xinan Jiao, Lin Sun
{"title":"Genomic evidence of clonal and IncX3 plasmid-mediated dissemination of blaNDM-7 in the Klebsiella pneumoniae complex.","authors":"Yujing Zhang, Guqi Ren, Jing Wu, Jun Xu, Yan Ji, Guiling Li, Zhenyu Wang, Jing Wang, Xinan Jiao, Lin Sun","doi":"10.1093/jac/dkag346","DOIUrl":"https://doi.org/10.1093/jac/dkag346","url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant Enterobacterales (CRE), particularly those carrying New Delhi metallo-β-lactamase (NDM) variants, pose a major global health threat. Among these, NDM-7 has attracted increasing attention due to its enhanced carbapenemase activity and clinical relevance. This study investigated the prevalence, genomic characteristics and dissemination of blaNDM-7-positive Klebsiella pneumoniae complex isolates from clinical and environmental sources in Yangzhou, China.</p><p><strong>Methods: </strong>A total of 401 clinical isolates, 282 hospital surface swabs and 366 wastewater samples collected between 2018 and 2024 were screened for blaNDM. Antimicrobial susceptibility testing and whole-genome sequencing were performed to characterize resistance profiles, genomic features and phylogenetic relationships. Conjugation and serial-passage assays were used to assess plasmid transferability and stability, respectively.</p><p><strong>Results: </strong>Seven blaNDM-7-positive isolates were identified, including one clinical isolate, one hospital environmental isolate and five wastewater isolates. All exhibited multidrug resistance. The blaNDM-7 gene was located on highly conserved ∼46 kb IncX3 plasmids that exhibited high conjugation frequencies (10-5-10-4) and stability (96.0%-98.7% mean retention after approximately 600 generations). Phylogenetic analysis revealed close genomic relatedness among the six ST196 K. quasipneumoniae isolates recovered from different sources, with only 0-7 core-genome SNP differences. All six isolates were recovered within approximately 6 months, consistent with recent common ancestry and possible clonal dissemination across settings.</p><p><strong>Conclusions: </strong>The close genomic relatedness of ST196 isolates from different sources supports possible clonal dissemination, while the high conservation, transferability and stability of IncX3 plasmids highlight their important role in the dissemination of blaNDM-7. These findings underscore the importance of continued genomic surveillance of blaNDM-7 and its associated mobile genetic elements across clinical and environmental settings.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on: 'Acute kidney injury in Staphylococcus aureus bacteremia: a multicentre cohort study of incidence, timing, recovery, and associations with antibiotic treatment'.","authors":"Hui Luo, Ting Ye","doi":"10.1093/jac/dkag366","DOIUrl":"10.1093/jac/dkag366","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lara M Almeida, Felipe M Zorzi, Kawany M Araujo, Joas L Silva, Andrea M Moreno, Paulo Bispo, Michael S Gilmore
{"title":"Phylogenetic diversification of the PoxtA ribosomal protection determinant.","authors":"Lara M Almeida, Felipe M Zorzi, Kawany M Araujo, Joas L Silva, Andrea M Moreno, Paulo Bispo, Michael S Gilmore","doi":"10.1093/jac/dkag339","DOIUrl":"https://doi.org/10.1093/jac/dkag339","url":null,"abstract":"<p><strong>Objectives: </strong>Three ATP-binding cassette subfamily F (ABC-F) PoxtA protein sequences are currently represented in NCBI's Pathogen Detection Reference Gene Catalog (WP_002415638.1, WP_209691075.1, and WP_094899500.1), while the number of publicly available sequences has steadily increased. We therefore conducted a curated survey of PoxtA homologue diversity, distribution, amino acid variability, and dissemination-associated genetic contexts.</p><p><strong>Methods: </strong>WP accessions were retrieved using BLASTp nr and a corresponding data package was obtained from NCBI Datasets v18.0.1. Proteins were aligned with MAFFT v7.525, clustered with CD-HIT v4.8.1, and maximum likelihood trees inferred in IQ-TREE v2.4.0. Gene occurrence derived from GCF assemblies containing host or source metadata. Genetic contexts were then investigated through sequence alignments of genomic regions extracted from these datasets.</p><p><strong>Results: </strong>Among 83 non-redundant PoxtA-related WP accessions retrieved, 21 homologues clustered with canonical RefSeq PoxtA proteins, while the remaining proteins were more distantly related to ABC-F. Predominantly associated with Bacillota, homologues exhibited broad distribution across clinical, agricultural, food-associated, and environmental sources. Substitutions potentially affecting their ribosome interactions were identified mainly within the Arm subdomain and the antibiotic-resistance domain. Genomes encoding homologues exhibited diverse genetic contexts, including partial conservation of Tn6657, intact Tn6246 and Tn8026 structures, and atypical contexts carrying additional resistance genes.</p><p><strong>Conclusions: </strong>Homologue diversification suggests ongoing adaptation and highlights an expanding repertoire of amino acid substitutions with yet unresolved structural and functional impacts. Genetic contexts likely underlie intra- and interspecies horizontal dissemination of homologue genes by promoting co-selection under antimicrobial selective pressures.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beyond susceptibility: pharmacokinetic and pharmacodynamic constraints of existing oral antibiotics in extensively drug-resistant typhoid fever.","authors":"Yamuna Devi Bakthavatchalam, Priscilla Rupali, Jacob John, Kamini Walia, Vasant Nagvekar, Balaji Veeraraghavan","doi":"10.1093/jac/dkag332","DOIUrl":"https://doi.org/10.1093/jac/dkag332","url":null,"abstract":"<p><p>Salmonella Typhi is an invasive pathogen with sustained bacteraemia and intracellular persistence, requiring therapy that achieves systemic exposure and intracellular penetration. Clinical efficacy should remain central to therapeutic decision-making, while pharmacokinetic/pharmacodynamic (PK/PD) analyses provide complementary insights into dose optimization and the pharmacological limitations of candidate therapies. Oral therapy remains central to typhoid fever management, particularly in South and Southeast Asia, where most patients are managed in the outpatient setting. However, the emergence of MDR and extensively drug-resistant (XDR) S. Typhi has substantially narrowed the available oral treatment options. Azithromycin remains the only widely available oral agent with established clinical efficacy, but emerging resistance threatens its continued utility. Several alternative oral agents, including mecillinam, faropenem, tebipenem, fosfomycin and β-lactam/β-lactamase inhibitor combinations, demonstrate favourable in vitro activity against S. Typhi. However, robust clinical efficacy and contemporary PK/PD data are lacking to support their use against MDR and XDR S. Typhi. Addressing these evidence gaps through integrated PK/PD investigations and prospective clinical trials will be essential to expand the oral therapeutic armamentarium for typhoid fever.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carla Concha Fuentes, Ainhoa Castiella-Aranzasti, Joaquín Burgos-Cibrián, Patricia Monzo-Gallo, Antonio Gallardo-Pizarro, Cynthia Terrones-Campos, Ana Martinez-Urrea, Carolina Galindo Contador, Andrea Vergara, Marta Bodro, Alex Soriano, Carolina Garcia-Vidal
{"title":"Successful management of histoplasmosis with novel triazole antifungals: a brief report.","authors":"Carla Concha Fuentes, Ainhoa Castiella-Aranzasti, Joaquín Burgos-Cibrián, Patricia Monzo-Gallo, Antonio Gallardo-Pizarro, Cynthia Terrones-Campos, Ana Martinez-Urrea, Carolina Galindo Contador, Andrea Vergara, Marta Bodro, Alex Soriano, Carolina Garcia-Vidal","doi":"10.1093/jac/dkag370","DOIUrl":"https://doi.org/10.1093/jac/dkag370","url":null,"abstract":"<p><strong>Objectives: </strong>Standard therapy for histoplasmosis is often limited by drug-drug interactions, toxicity and variable pharmacokinetics. We report clinical experience using the novel triazoles posaconazole and isavuconazole as alternative treatment options.</p><p><strong>Methods: </strong>A retrospective case series was conducted. We analysed six cases of confirmed histoplasmosis (identified by culture, histopathology or PCR) in patients hospitalized in Barcelona, Spain, between 2017 and 2022. Patients received posaconazole delayed-release tablets (300 mg daily) or isavuconazole capsules (200 mg daily) as primary or step-down therapy. Complete response was defined as the resolution of all attributable signs and symptoms with microbiological clearance and/or radiological improvement when available.</p><p><strong>Results: </strong>The cohort included immunocompromised and immunocompetent patients with disseminated (n = 3), localized (n = 2) and chronic cavitary pulmonary (n = 1) histoplasmosis. Comorbidities included HIV, chronic lymphocytic leukaemia and corticosteroid use. Novel triazoles were utilized as step-down therapy after liposomal amphotericin B (LAmB) induction (n = 5) or as primary oral therapy (n = 1) for a median duration of 11.75 months. One patient with severe intestinal involvement received isavuconazole following itraconazole-induced hepatotoxicity and short-course LAmB. All six patients (100%) achieved complete clinical, radiological and/or mycological response without evidence of toxicity or relapse during 1-5 years of follow-up.</p><p><strong>Conclusions: </strong>These findings contribute real-world evidence supporting the potential role of posaconazole and isavuconazole as alternative therapeutic options for confirmed histoplasmosis given their favourable safety profile, long-term tolerability and clinical outcomes in our series. Larger multicentre comparative studies are needed to better define the role of novel triazoles compared with the current standard of care (itraconazole).</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andres Mazariegos Herrera, Mats O Karlsson, Elin M Svensson, Thomas P C Dorlo
{"title":"Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis-right-to-reply.","authors":"Andres Mazariegos Herrera, Mats O Karlsson, Elin M Svensson, Thomas P C Dorlo","doi":"10.1093/jac/dkag352","DOIUrl":"10.1093/jac/dkag352","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"'Acute kidney injury in Staphylococcus aureus bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment'-right-to-reply.","authors":"F S Sinkeler, M P M Hensgens, R J Brüggemann","doi":"10.1093/jac/dkag367","DOIUrl":"https://doi.org/10.1093/jac/dkag367","url":null,"abstract":"","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Mercedes Santoro, Daniele Spalletta, Vincenzo Spagnuolo, Chiara Paletti, Greta Marchegiani, Maria Concetta Bellocchi, Riccardo Lolatto, Luca Carioti, Adriana Cervo, Antonio Di Biagio, Marta Fiscon, Emanuele Focà, Roberta Gagliardini, Stefano Rusconi, Maurizio Zazzi, Antonella Castagna, Francesco Saladini, Francesca Ceccherini-Silberstein
{"title":"Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry.","authors":"Maria Mercedes Santoro, Daniele Spalletta, Vincenzo Spagnuolo, Chiara Paletti, Greta Marchegiani, Maria Concetta Bellocchi, Riccardo Lolatto, Luca Carioti, Adriana Cervo, Antonio Di Biagio, Marta Fiscon, Emanuele Focà, Roberta Gagliardini, Stefano Rusconi, Maurizio Zazzi, Antonella Castagna, Francesco Saladini, Francesca Ceccherini-Silberstein","doi":"10.1093/jac/dkag335","DOIUrl":"10.1093/jac/dkag335","url":null,"abstract":"<p><strong>Background: </strong>Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor, approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR). To date, few data are available on resistance profiles in real life.</p><p><strong>Methods: </strong>Paired plasma and PBMC samples from nine HTE PWH with MDR enrolled in the PRESTIGIO Registry receiving LEN in combination with an optimized background regimen were collected before (baseline) and during LEN treatment. Next-generation sequencing was performed using in-house protocols. LEN susceptibility was assessed by single-cycle assay. Intra-patient viral evolution was evaluated through quasispecies distance analysis.</p><p><strong>Results: </strong>At baseline, no major LEN resistance-associated mutations were detected; the accessory capsid polymorphism T107A was identified as a minority variant (5.9%) in one case, with phenotypic assays confirming full LEN susceptibility (mean fold-change: 1.2). Participants received LEN for a median [IQR] of 19.8 [18.5-23.2] months. Two individuals started LEN with undetectable viremia and maintained suppression. The other seven participants were viremic; six achieved viral suppression, with one experiencing a blip. One low-adherent participant exhibited persistent viremia with Q67K and K70H as the majority variants in both plasma (98.5%; 97.8%) and PBMCs (75.7%; 75.6%), conferring a 2081-fold reduction in LEN susceptibility. Intra-host variability in the capsid and pol regions remained low over time and across compartments.</p><p><strong>Conclusions: </strong>In this case series of HTE PWH with MDR, LEN was highly associated with maintenance or achievement of virological suppression and limited virus evolution, with only one participant remaining viremic and showing a majority highly LEN-resistant variant.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francisco Javier Candel, Mayra Matesanz, Ana Muñoz-Gómez, Jose L Del Pozo
{"title":"Cross-susceptibility among tetracyclines in Gram-positive infections: microbiological basis, EUCAST/CLSI guidance and clinical implications for doxycycline use.","authors":"Francisco Javier Candel, Mayra Matesanz, Ana Muñoz-Gómez, Jose L Del Pozo","doi":"10.1093/jac/dkag353","DOIUrl":"https://doi.org/10.1093/jac/dkag353","url":null,"abstract":"<p><strong>Background: </strong>Tetracyclines remain useful options for Gram-positive infections, particularly when prolonged oral therapy is required. Doxycycline is attractive because of its oral bioavailability and tolerability, but many susceptibility systems report tetracycline or minocycline rather than doxycycline, creating uncertainty about within-class extrapolation.</p><p><strong>Objectives: </strong>To examine the microbiological, pharmacokinetic/pharmacodynamic (PK/PD), interpretive and clinical evidence supporting cross-susceptibility among tetracycline-class agents in clinically relevant Gram-positive organisms and to define when surrogate results may reasonably support doxycycline use.</p><p><strong>Methods: </strong>We performed a narrative review of PubMed/MEDLINE and ScienceDirect (1990-2025), supplemented by current European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) documents. Predefined search concepts covered resistance mechanisms, cross-susceptibility, PK/PD and clinical outcomes. Primary microbiological, surveillance, PK/PD and clinical studies and systematic reviews/meta-analyses were prioritized.</p><p><strong>Results: </strong>Cross-susceptibility is not uniform across the tetracycline class. Efflux mechanisms such as tet(K) and tet(L) may permit retained doxycycline or minocycline activity, whereas ribosomal protection mechanisms such as tet(M) and tet(O) are associated with broader reduced susceptibility. Interpretation is organism-, phenotype-, method- and breakpoint-dependent. Free-drug Area Under the Concentration-Time Curve (AUC)/Minimun Inhibitory Concentration (MIC) is the principal PK/PD index, but exposure targets vary by agent, pathogen, model and endpoint. Direct clinical evidence is heterogeneous and is strongest for selected staphylococcal osteoarticular infections and suppressive therapy.</p><p><strong>Conclusions: </strong>Organism-specific EUCAST or CLSI surrogate rules may provide sufficient microbiological support for doxycycline use without routine agent-specific MIC confirmation when the clinical context is appropriate. Direct doxycycline testing is particularly valuable when surrogate interpretation is unsupported, results are resistant or discordant or uncertainty could materially affect management of severe or deep-seated infection.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":"81 11","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}